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1. History of cancer immunotherapy
Cancer immunotherapy has become an innovative approach that both pushes 
the medical and scientific community to better understand our own immune 
system and charts a new frontier in the fight against one of the leading killers in the 
world, cancer. The advent of this line of work dates back to the discovery of vaccine. 
Luminary scientists in the nineteenth century such as Joseph Lister, Louis Pasteur, 
Robert Koch, and most notably William Coley have allowed for a better understand-
ing of the immune responses and the establishment of vaccines, including vaccines 
directed against malignant tumors [1–4].
While the basic concept of using immunotherapy to combat cancer was 
practiced in the scientific community, specifically by Coley, scientists Thomas 
and Burney were the first to propose the theory of cancer immunosurveillance in 
1957. The premise behind their theory was that lymphocytes, an integral part of 
the immune system, have the capability to eliminate the mutated cancerous cells 
throughout the human body [5–8]. However, due to a lack of scientific proof-of-
concept and the inability to culture the lymphocytes ex vivo for extended periods of 
time, the next development did not occur until a few decades later. From the 1970s 
onward, the scientific community has discovered the utility of several different 
immune therapies to treat cancer including interferon alpha (IFN-α) [9], the T cell 
growth factor interleukin 2 (IL-2), monoclonal antibodies targeting tumor-associ-
ated antigens, and the first FDA-approved cell-based cancer vaccine developed for 
patients with advanced prostate cancer in 2010 (Figure 1).
This chapter will give a brief overview of few of these therapies that scientists 
and physicians are currently utilizing in the fight against cancer.
2. Tumor antigens
Tumor cells are distinguished from normal cells in a tissue by the presence of 
unique proteins known as tumor antigens. They can be further divided into two 
broad categories, tumor-associated antigens and tumor-specific antigens.
Tumor-associated antigens can arise from oncofetal genes that become aber-
rantly expressed in malignant cells, such as alpha-fetoprotein (AFP) in liver 
cancer and the melanoma-specific antigens of the MAGE family [10], or from 
cancer-testis antigens that are expressed normally in the germ cells and become 
activated in cancers, such as the New York esophageal squamous cell carcinoma 
1 (NY-ESO-1) antigen [11]. Tumor-associated antigens also include tissue 
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differentiation antigens, such as tyrosinase in melanoma [12], and viral antigens in 
a number of malignancies where viral oncogenesis is implicated, such as HPV E6 
and E7 oncoproteins in HPV-associated cervical cancers [13]. On the other hand, 
tumor-specific antigens are usually the products of mutated oncogenes or tumor 
suppressor genes, such as ras and p53.
3. Cancer vaccines
While it is well established that vaccines are a way to stimulate the immune 
system against infectious agents, the concept of harnessing the power of a vaccine 
to eliminate cancers remains revolutionary. Cancer vaccines work through inducing 
a specific antitumor T cell response.
Cancer vaccines are divided into prophylactic and therapeutic vaccines. For 
instance, a prophylactic vaccine against human papillomavirus (HPV) can prevent 
several cancer types caused by virus, such as cervical cancer and some cancers of 
the oropharynx [14, 15], and hepatitis B virus (HBV) vaccine provides protection 
against liver cancers initiated by the hepatitis B virus [16]. Alternatively, thera-
peutic cancer vaccines trigger an immune response against an existing tumor by 
inducing T cell response within the tumor microenvironment. Various formats have 
been developed for therapeutic cancer vaccines, including peptide fragments and 
full-length tumor antigens, vectors for genetically encoded tumor antigens, whole 
tumor cell contents, and autologous dendritic cell (DC) vaccines. Most notably, 
Sipuleucel-T (Provenge) was the first FDA-approved cell-based cancer vaccine 
developed for patients with hormone-refractory prostate cancer and has shown to 
prolong the life of affected patients by several months [17, 18].
Figure 1. 
Key events in the history of cancer immunotherapy.
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Since most tumor-associated antigens are not highly immunogenic on their own, 
an immune adjuvant is typically added to vaccine formulas. Examples of vaccine 
adjuvants include recombinant granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and heat shock proteins [19–21].
4. Adoptive cellular immunotherapy
Adoptive cellular immunotherapy (ACT) is the process of transferring effec-
tor immune cells, such as T lymphocytes, to cancer patients, including modifying 
and expanding these immune cells ex vivo to target specific cancer cells [22, 23]. 
The transferred immune cells can have autologous or allogeneic origin. Two major 
approaches have been utilized for adoptive cellular immunotherapy, tumor-infil-
trating lymphocytes (TILs) and chimeric antigen receptor-modified T cell (CAR-T) 
therapy.
4.1 Tumor-infiltrating lymphocytes (TILs)
A tumor-infiltrating lymphocyte is an immune cell that has moved into a tumor 
in the attempt to destroy the cancer. In this therapy, TILs are extracted from tumor 
tissue biopsies and cultured in vitro with IL-2 to expand the tumor-reactive clones. 
Once activated, lymphocytes are infused back into the patient [24].
4.2 Chimeric antigen receptor-modified T cell (CAR-T) therapy
Chimeric antigen receptor-modified T cell (CAR-T) therapy has emerged 
as a successful method in the fight against cancer, especially B cell hematologic 
malignancies [25]. This success lies within the chimeric antigen receptors (CAR) 
composed of single-chain variable fragment (scFv) and the costimulatory signaling 
molecules that can stimulate T cells and allow for direct antigen binding and activa-
tion, bypassing the requirement for antigen presentation by antigen-presenting 
cells (APCs).
CAR-T cell therapy has been especially effective against certain types of lym-
phoma and leukemia, such as refractory B cell lymphoma and acute lymphoblastic 
leukemia (ALL) [26, 27]. CAR-T cell therapy is a multistep process. First, patients 
are evaluated to determine if CAR-T cell therapy is an appropriate treatment. 
Second, T cells are isolated from blood. The patient’s T cells are then taken into the 
laboratory to be genetically modified to express the chimeric antigen receptors 
(CARs) on their surfaces. As discussed above, these essential receptors allow for the 
modified T cells to recognize tumor antigens. Finally, the CAR-T cells are infused 
back into the patient, and a recovery period of 2–3 months is expected [28].
Overall, CAR-T cell therapy has become a leading area of continued growth and 
research in the field of cancer immunotherapy. It has had much success in both pre-
clinical and clinical applications, and the next steps involve harnessing the power 
of modified T cells to aid in eliminating solid tumors including aggressive cancers, 
such as sarcomas.
4.3 NK cell therapy
Natural killer (NK) cells are large granular lymphocytes that can destroy cells 
organically, without the requirement for priming first. One of the major hypotheses 
related to NK cells is the “missing self” hypothesis, which states that NK cells have 
the ability to destroy cells that do not display major histocompatibility complex 
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(MHC) class I molecules [29]. Given the extraordinary functions of NK cells in 
recognizing and destroying altered cells, NK cell-based therapies have become a 
wide area of research for diseases like cancer. One such targeted therapy is the use 
of NK alloreactivity, specifically in acute leukemia and other types of hematologic 
cancers. MHC class I inhibitory receptors, specifically killer immunoglobulin-like 
receptors (KIRs), have been utilized to exert NK cell alloreactivities as a way to 
combat leukemic cells [30].
5. Antibody-based treatments
Antibodies are arguably one of the most important aspects of the human 
immune system. They serve to bind to antigens and allow for flagging of cells with 
specific antigens for eradication. An antitumor monoclonal antibody is a genetically 
engineered immunoglobulin that is produced to recognize a specific tumor antigen 
on the surface of a cancer cell [31].
Monoclonal antibodies work in a multitude of ways including flagging cancer 
cells, blocking growth of cells, blocking immune inhibitors, directly attacking 
cancer cells, and bridging cancer and immune cells [32]. Monoclonal antibodies 
come in two different varieties, naked and conjugated. Naked monoclonal antibod-
ies work individually and can attach themselves to antigens on cancer cells. For 
instance, trastuzumab (Herceptin) can bind to HER2 oncogene/tumor antigen 
that is overexpressed in a subset of breast cancers, which blocks the growth and 
proliferation of the malignant cells [33]. Conjugated monoclonal antibodies work 
by carrying a radioactive or cytotoxic drug into proximity to the tumor cells, thus 
killing these malignant cells [34, 35]. As with other cancer immunotherapies, 
antibody-based treatments carry the risk of adverse side effects that include fever, 
weakness, nausea, and rashes.
6. Immune checkpoint inhibitors
Immune checkpoint inhibitors are inhibitory molecules on immune cells that 
prevent the immune system from attacking the organism’s own tissues. Two of the 
identified immune checkpoints are programmed cell death-1 (PD-1) and cytotoxic 
T lymphocyte-associated protein 4 (CTLA-4) [36].
Interaction of PD-1 and its ligand PDL-1 leads to T lymphocytes’ dysfunc-
tion and exhaustion. PDL-1 is shown to be highly expressed on cancer cells 
[37]. Consequently, the blockage of PD-1 and PDL-1 interactions using immune 
checkpoint inhibitors allows tumor-specific T lymphocytes to exert their function 
by recognizing and destroying cancer cells. Nivolumab and pembrolizumab are 
monoclonal antibodies that function as PD-1 blockers and are being currently being 
used to treat patients with advanced melanoma and non-small cell lung cancer 
[38, 39]. Similarly, CTLA-4 inhibits T cell activation. Thus, CTLA-4 blockage with 
inhibitors, such as ipilimumab, enhances the immune responses against malignant 
tumors such as melanoma [40].
It is important to note, however, that the use of immune checkpoint inhibitors 
in cancer immunotherapy is frequently followed by inflammatory and autoimmune 
side effects that include endocrine effects, rash, and hepatitis [41, 42].
In conclusion, cancer immunotherapy remains a field that has tremendously 
changed our understanding of how to best treat cancers. While advancements 
have been made, there are many more discoveries to be made as the field of tumor 
immunology is growing exponentially.
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